CliffBio
small molecule

ATTRUBY

ACORAMIDIS HYDROCHLORIDE

Loss of exclusivityAugust 2039latest FDA-listed patent expiry
CompanyBridgeBio →View the full company profile on CliffBio

Drug detail

Brand nameATTRUBY
Active ingredientACORAMIDIS HYDROCHLORIDE
StrengthEQ 356MG BASE
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalNovember 2024
Marketing statusRX

Listed patents

PatentExpiresType
11260047August 2039product
12005043August 2039product
12539290August 2039product
12070449March 2039use U-4046
11058668March 2039use U-4046
10513497February 2038substance
11919865February 2038use U-4046
8877795May 2031product
9913826May 2031use U-4046
9642838May 2031substance, product
10398681May 2031product
10842777May 2031use U-4046
9169214May 2031product

Regulatory exclusivity

CodeExpires
ODE-506November 2031
NCENovember 2029

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

ATTRUBY patent cliff — loss of exclusivity August 2039 | CliffBio